Arch Therapeutics (ARTH) Stock Price, News & Analysis

Company Overview

Arch Therapeutics, Inc. is a medical device company focused on designing and commercializing synthetic self-assembling peptide technologies to address unmet needs in surgical, wound care and emergency medicine. The company’s proprietary platform, known as AC5®, leverages short-chain peptides that rapidly form an extracellular matrix–like hydrogel upon contact with physiological fluids. This material is being developed to achieve hemostasis, seal tissue, and promote healing in a wide range of clinical settings.

Arch Therapeutics’ lead product candidate is AC5 Surgical Hemostatic Device, which aims to control non‐compressible bleeding during surgical procedures. Additional applications of the AC5 technology include an advanced wound care formulation for chronic wounds and a pulmonary sealant designed to manage air leaks following thoracic surgery. The company’s research and development efforts are centered on advancing these products through preclinical studies and regulatory pathways toward clinical use.

Founded in the mid-2000s and headquartered in Framingham, Massachusetts, Arch Therapeutics operates primarily in the United States, with strategic partnerships under exploration in Europe and Asia to extend its global reach. The company maintains collaborations with leading academic institutions and contract research organizations to support its pipeline development. Arch Therapeutics is led by a management team and board of directors with extensive experience in biotechnology, medical device commercialization and regulatory affairs, reflecting a commitment to translating innovative science into practical clinical solutions.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.00 to $0.24
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 4,068 shs
• Market Capitalization: $763 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ARTH Stock Analysis - Frequently Asked Questions

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics, Inc. (OTCMKTS:ARTH) announced its earnings results on Thursday, July, 23rd. The biotechnology company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01.

How do I buy shares of Arch Therapeutics?

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arch Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arch Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Arista Networks (ANET), Adobe (ADBE), GE Aerospace (GE) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 7/23/2020
• Today: 7/18/2025
• Next Earnings (Estimated): 8/18/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:ARTH
• Previous Symbol: NASDAQ:ARTH
• CIK: 1537561
• Web: www.archtherapeutics.com
• Phone: (617) 431-2313
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.98 million
• Net Margins: -8,257.70%
• Pretax Margin: -8,257.70%
• Return on Equity: N/A
• Return on Assets: -730.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.10
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: $80 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.43) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,742,000
• Free Float: 4,529,000
• Market Cap: $763 thousand
• Optionable: Not Optionable
• Beta: 4.02